Next generation sequencing in clinical medicine: Challenges and lessons for pathology and biomedical informatics
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
The Human Genome Project (HGP) provided the initial draft of mankind's DNA sequence in 2001. The HGP was produced by 23 collaborating laboratories using Sanger sequencing of mapped regions as well as shotgun sequencing techniques in a process that occupied 13 years at a cost of ~$3 billion. Today, Next Generation Sequencing (NGS) techniques represent the next phase in the evolution of DNA sequencing technology at dramatically reduced cost compared to traditional Sanger sequencing. A single laboratory today can sequence the entire human genome in a few days for a few thousand dollars in reagents and staff time. Routine whole exome or even whole genome sequencing of clinical patients is well within the realm of affordability for many academic institutions across the country. This paper reviews current sequencing technology methods and upcoming advancements in sequencing technology as well as challenges associated with data generation, data manipulation and data storage. Implementation of routine NGS data in cancer genomics is discussed along with potential pitfalls in the interpretation of the NGS data. The overarching importance of bioinformatics in the clinical implementation of NGS is emphasized.[7] We also review the issue of physician education which also is an important consideration for the successful implementation of NGS in the clinical workplace. NGS technologies represent a golden opportunity for the next generation of pathologists to be at the leading edge of the personalized medicine approaches coming our way. Often under-emphasized issues of data access and control as well as potential ethical implications of whole genome NGS sequencing are also discussed. Despite some challenges, it's hard not to be optimistic about the future of personalized genome sequencing and its potential impact on patient care and the advancement of knowledge of human biology and disease in the near future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368 · cited 1×
“[49] With NGS technologies, it is possible to scan the entire genome for the presence or absence of mutations in an unbiased fashion.”
MethodVerhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575 · cited 2×
“Multiple alterations occurring in different types of cancer include mutations, translocations, copy number alterations in the form of gains and losses,[14-17] complex karyotypic rearrangements and epigenetic changes.”
BackgroundSequencing technologies – the next generation
Metzker, M. L. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2626 · Cited by 7,066 · cited 1×
“The reader is referred to exhaustive reviews of the next generation technology platforms and their unique distinguishing characteristics [6-8] for more details [Table 1].”
BackgroundThe ENCODE Project Consortium (2007) · Nature · doi:10.1038/nature05874 · Cited by 5,223 · cited 1×
“[60-63] In this context, NGS platforms offer additional versatility and application in transcriptomic profiling (as demonstrated by Mortazavi et al[64]), chromatin immunoprecipitation, small RNA’s and epigenomics studies (discussed below).”
BackgroundThe landscape of somatic copy-number alteration across human cancers
Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017
SOAP: Short oligonucleotide alignment program
Li, R., Li, Y., Kristiansen, K., & Wang, J. (2008) · Bioinformatics · doi:10.1093/bioinformatics/btn025 · Cited by 3,597 · cited 2×
“Some of the freely available versions include MAQ, [36] BWA, [37] Bowtie, [38] SOAP, [39] ZOOM, [40] SHRiMP [41] and Novoalign.”
MethodA rapid method for determining sequences in DNA by primed synthesis with DNA polymerase
Sanger, F., & Coulson, A. R. (1975) · Journal of Molecular Biology · doi:10.1016/0022-2836(75)90213-2 · Cited by 2,709 · cited 1×
“pioneering work of Walter Gilbert[1] and Frederick Sanger.[2] Continuous technological improvements in DNA sequencing instrumentation ever since has created an environment in which the Human Genome Project (HGP) [3] could be finally realized in the year 2001 after a decade of work.”
BackgroundMapping short DNA sequencing reads and calling variants using mapping quality scores
Li, H., Ruan, J., & Durbin, R. (2008) · Genome Research · doi:10.1101/gr.078212.108 · Cited by 2,638
KEGG for representation and analysis of molecular networks involving diseases and drugs
Kanehisa, M., Goto, S., Furumichi, M., Tanabe, M., & Hirakawa, M. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkp896 · Cited by 2,322 · cited 1×
“[11,25] Several groups have used principles of network theory to develop software tools and databases capable of displaying complex biological interactions such as (KEGG,[26] Cytoscape,[27] IPA (http:// www.”
MethodMAQC Consortium, Shi, L., Shi, L., Reid, L. H., Jones, W. D., Shippy, R., Warrington, J. A., Baker, S. C., Collins, P. J., de Longueville, F., et al. (2006) · Nature Biotechnology · doi:10.1038/nbt1239 · Cited by 2,126 · cited 1×
“Guidelines for standardization of NGS protocols, along the lines of-efforts initiated by the FDA: the microarray quality control (MAQC) project [73] and the sequencing quality control (SEQC) project (http:// www.fda.gov/MicroArrayQC/), will be particularly important for NGS going forward.”
BackgroundThe patterns and dynamics of genomic instability in metastatic pancreatic cancer
Campbell, P. J., Yachida, S., Mudie, L. J., Stephens, P. J., Pleasance, E. D., Stebbings, L. A., Morsberger, L. A., Latimer, C., McLaren, S., Lin, M.-L., et al. (2010) · Nature · doi:10.1038/nature09460 · Cited by 1,317
Human Genome Sequencing Using Unchained Base Reads on Self-Assembling DNA Nanoarrays
Drmanac, R., Sparks, A. B., Callow, M. J., Halpern, A. L., Burns, N. L., Kermani, B. G., Carnevali, P., Nazarenko, I., Nilsen, G. B., Yeung, G., et al. (2010) · Science · doi:10.1126/science.1181498 · Cited by 1,212 · cited 1×
“[4,5] Several NGS technologies have been developed using diverse approaches since 2001, each with its own distinctive strengths and weaknesses.”
MethodCharacterizing the cancer genome in lung adenocarcinoma
Weir, B. A., Woo, M. S., Getz, G., Perner, S., Ding, L., Beroukhim, R., Lin, W. M., Province, M. A., Kraja, A., Johnson, L. A., et al. (2007) · Nature · doi:10.1038/nature06358 · Cited by 1,105 · cited 1×
“…technologies is in no doubt and has been successfully utilized to identify variations in different types of cancer such as lung cancer, melanomas and breast cancer at a single nucleotide level, [14,16,18,58,59] significant hurdles still remain in scaling these algorithms to the chromosomal level.”
BackgroundClinical assessment incorporating a personal genome
Ashley, E. A., Butte, A. J., Wheeler, M. T., Chen, R., Klein, T. E., Dewey, F. E., Dudley, J. T., Ormond, K. E., Pavlovic, A., Morgan, A. A., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60452-7 · Cited by 674
Integrative analysis of the melanoma transcriptome
Berger, M. F., Levin, J. Z., Vijayendran, K., Sivachenko, A., Adiconis, X., Maguire, J., Johnson, L. A., Robinson, J., Verhaak, R. G., Sougnez, C., et al. (2010) · Genome Research · doi:10.1101/gr.103697.109 · Cited by 305 · cited 1×
“…technologies is in no doubt and has been successfully utilized to identify variations in different types of cancer such as lung cancer, melanomas and breast cancer at a single nucleotide level, [14,16,18,58,59] significant hurdles still remain in scaling these algorithms to the chromosomal level.”
BackgroundWhat would you do if you could sequence everything?
Kahvejian, A., Quackenbush, J., & Thompson, J. F. (2008) · Nature Biotechnology · doi:10.1038/nbt1494 · Cited by 189 · cited 1×
“[9] Whole-genome sequencing will form the basis of the new field of personalized ‘genomic medicine’ [10,11] that aims to integrate the clinical symptoms, personal and family history and the patient’s genomic DNA sequence to provide healthcare that is personalized and unique.”
Background
Cited by
Sambamba: fast processing of NGS alignment formats
Tarasov, A., Vilella, A. J., Cuppen, E., Nijman, I. J., & Prins, P. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btv098 · Cited by 2,413
College of American Pathologists' Laboratory Standards for Next-Generation Sequencing Clinical Tests
Aziz, N., Zhao, Q., Bry, L., Driscoll, D. K., Funke, B., Gibson, J. S., Grody, W. W., Hegde, M. R., Hoeltge, G. A., Leonard, D. G. B., et al. (2015) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2014-0250-cp · Cited by 387
Eberle, M. A., Fritzilas, E., Krusche, P., Källberg, M., Moore, B. L., Bekritsky, M. A., Iqbal, Z., Chuang, H.-Y., Humphray, S. J., Halpern, A. L., et al. (2017) · Genome Research · doi:10.1101/gr.210500.116 · Cited by 354
Greiff, V., Bhat, P., Cook, S. C., Menzel, U., Kang, W., & Reddy, S. T. (2015) · Genome Medicine · doi:10.1186/s13073-015-0169-8 · Cited by 181
Squidiff: predicting cellular development and responses to perturbations using a diffusion model
He, S., Zhu, Y., Tavakol, D. N., Ye, H., Lao, Y.-H., Zhu, Z., Xu, C., Chauhan, S., Garty, G., Tomer, R., et al. (2026) · Nature Methods · doi:10.1038/s41592-025-02877-y · Cited by 38
“Exploring disease mechanisms and optimizing drug components require large-scale sequencing screens, which are laborious and expensive 4,5 .”
Metadata
- Authors
- Gullapalli, R. R., Desai, K. V., Santana-Santos, L., Kant, J. A., & Becich, M. J.
- Venue
- Journal of Pathology Informatics
- Publisher
- Elsevier BV
- Published
- 2012-01
- Volume
- 3
- Issue
- 1
- Pages
- 40
- ISSN
- 2153-3539 (ISSN-L)
- OpenAlex
- W2163553106
- Cited by
- 157
- References
- 16
- FWCI
- 9.21
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.